Ravi Mehrotra Recent News
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
Credit Suisse Views Celgene As 'Underappreciated'
UPDATE: Credit Suisse Downgrades InterMune as Balanced Risk/Reward is Reflected in Price
Credit Suisse Reiterates on Biogen Idec on Positive RDP Decision
UPDATE: Credit Suisse Raises PT on Biogen Idec on Higher Tecfidera and Hemophilia Sales Estimates
UPDATE: Credit Suisse Initiates Receptos at Outperform on R&D Focus